EA201991513A1 - Производные пирана как ингибиторы cyp11a1 (цитохром p450 монооксигеназы 11a1) - Google Patents
Производные пирана как ингибиторы cyp11a1 (цитохром p450 монооксигеназы 11a1)Info
- Publication number
- EA201991513A1 EA201991513A1 EA201991513A EA201991513A EA201991513A1 EA 201991513 A1 EA201991513 A1 EA 201991513A1 EA 201991513 A EA201991513 A EA 201991513A EA 201991513 A EA201991513 A EA 201991513A EA 201991513 A1 EA201991513 A1 EA 201991513A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cyp11a1
- monooxygenase
- cytochrome
- inhibitors
- pirana
- Prior art date
Links
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 title abstract 2
- 101710198130 NADPH-cytochrome P450 reductase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 108010084976 Cholesterol Side-Chain Cleavage Enzyme Proteins 0.000 title 1
- 102100027516 Cholesterol side-chain cleavage enzyme, mitochondrial Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 108010085012 Steroid Receptors Proteins 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 102000005969 steroid hormone receptors Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
Описаны соединения формулы (I), где R, R, R, R, R, R, R, L, A и B являются такими, как определено в п.1, или их фармацевтически приемлемые солиСоединения формулы (I) обладают эффективностью в качестве ингибиторов цитохром P450 монооксигеназы 11A1 (CYP11A1). Соединения могут использоваться в качестве лекарственных средств при лечении заболеваний и состояний, зависимых от стероидного рецептора, в частности андрогенного рецептора, таких как рак предстательной железы.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20166024 | 2016-12-22 | ||
| PCT/FI2017/050926 WO2018115591A1 (en) | 2016-12-22 | 2017-12-21 | Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201991513A1 true EA201991513A1 (ru) | 2019-11-29 |
| EA039309B1 EA039309B1 (ru) | 2022-01-12 |
Family
ID=61005837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201991513A EA039309B1 (ru) | 2016-12-22 | 2017-12-21 | Производные пирана как ингибиторы cyp11a1 (цитохром p450 монооксигеназы 11a1) |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10717726B2 (ru) |
| EP (2) | EP3868756A1 (ru) |
| JP (2) | JP7025432B2 (ru) |
| KR (2) | KR20230019496A (ru) |
| CN (2) | CN116162084A (ru) |
| AR (1) | AR110412A1 (ru) |
| AU (2) | AU2017380282B2 (ru) |
| BR (1) | BR112019012906A2 (ru) |
| CA (1) | CA3047370A1 (ru) |
| CL (1) | CL2019001728A1 (ru) |
| CO (1) | CO2019007321A2 (ru) |
| CY (1) | CY1124461T1 (ru) |
| DK (1) | DK3558981T3 (ru) |
| EA (1) | EA039309B1 (ru) |
| ES (1) | ES2880151T3 (ru) |
| HR (1) | HRP20211255T1 (ru) |
| HU (1) | HUE056540T2 (ru) |
| IL (2) | IL267484B (ru) |
| LT (1) | LT3558981T (ru) |
| MA (2) | MA47102B1 (ru) |
| MX (1) | MX2019007373A (ru) |
| PE (1) | PE20191137A1 (ru) |
| PH (1) | PH12019550111A1 (ru) |
| PL (1) | PL3558981T3 (ru) |
| PT (1) | PT3558981T (ru) |
| RS (1) | RS62198B1 (ru) |
| SI (1) | SI3558981T1 (ru) |
| TN (1) | TN2019000189A1 (ru) |
| TW (2) | TWI796205B (ru) |
| UA (1) | UA124640C2 (ru) |
| WO (1) | WO2018115591A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
| KR20230010723A (ko) | 2020-05-14 | 2023-01-19 | 오리온 코포레이션 | Cyp11a1 억제제 |
| AU2021391977A1 (en) | 2020-12-01 | 2023-07-13 | Orion Corporation | 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer |
| AR124985A1 (es) | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| CN117279893A (zh) | 2021-03-01 | 2023-12-22 | 奥仁公司 | 用于制备cyp11a1抑制剂及其中间体的方法 |
| WO2022184977A1 (en) | 2021-03-01 | 2022-09-09 | Orion Corporation | Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor |
| CN117836273A (zh) | 2021-06-23 | 2024-04-05 | 奥仁公司 | 用于制备cyp11a1抑制剂及其中间体的方法 |
| CN118076355A (zh) * | 2021-09-28 | 2024-05-24 | 奥仁公司 | 用于治疗前列腺癌的cyp11a1抑制剂 |
| WO2023073285A1 (en) | 2021-10-28 | 2023-05-04 | Orion Corporation | Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor |
| WO2023084158A1 (en) | 2021-11-10 | 2023-05-19 | Orion Corporation | Cyp11a1 inhibitors |
| WO2023139312A1 (en) | 2022-01-20 | 2023-07-27 | Orion Corporation | Pharmaceutical composition of a cyp11a1 inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176485A (ja) * | 1984-09-20 | 1986-04-18 | Ss Pharmaceut Co Ltd | 新規なγ−ピラン誘導体 |
| US7344700B2 (en) * | 2002-02-28 | 2008-03-18 | University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| EP1471063A1 (en) * | 2003-02-28 | 2004-10-27 | Exonhit Therapeutics S.A. | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| TW201534586A (zh) * | 2013-06-11 | 2015-09-16 | Orion Corp | 新穎ｃｙｐ１７抑制劑／抗雄激素劑 |
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2017
- 2017-12-20 AR ARP170103609A patent/AR110412A1/es unknown
- 2017-12-21 KR KR1020237002074A patent/KR20230019496A/ko not_active Application Discontinuation
- 2017-12-21 CN CN202211597796.4A patent/CN116162084A/zh active Pending
- 2017-12-21 JP JP2019534192A patent/JP7025432B2/ja active Active
- 2017-12-21 AU AU2017380282A patent/AU2017380282B2/en active Active
- 2017-12-21 CN CN201780079479.4A patent/CN110139861B/zh active Active
- 2017-12-21 ES ES17832250T patent/ES2880151T3/es active Active
- 2017-12-21 KR KR1020197021256A patent/KR102491308B1/ko active IP Right Grant
- 2017-12-21 EA EA201991513A patent/EA039309B1/ru unknown
- 2017-12-21 LT LTEP17832250.9T patent/LT3558981T/lt unknown
- 2017-12-21 MA MA47102A patent/MA47102B1/fr unknown
- 2017-12-21 WO PCT/FI2017/050926 patent/WO2018115591A1/en unknown
- 2017-12-21 PL PL17832250T patent/PL3558981T3/pl unknown
- 2017-12-21 PE PE2019001297A patent/PE20191137A1/es unknown
- 2017-12-21 TW TW111114824A patent/TWI796205B/zh active
- 2017-12-21 EP EP21165964.4A patent/EP3868756A1/en active Pending
- 2017-12-21 CA CA3047370A patent/CA3047370A1/en active Pending
- 2017-12-21 RS RS20210994A patent/RS62198B1/sr unknown
- 2017-12-21 MX MX2019007373A patent/MX2019007373A/es unknown
- 2017-12-21 DK DK17832250.9T patent/DK3558981T3/da active
- 2017-12-21 UA UAA201908272A patent/UA124640C2/uk unknown
- 2017-12-21 SI SI201730841T patent/SI3558981T1/sl unknown
- 2017-12-21 TW TW106145006A patent/TWI762544B/zh active
- 2017-12-21 PT PT178322509T patent/PT3558981T/pt unknown
- 2017-12-21 TN TNP/2019/000189A patent/TN2019000189A1/en unknown
- 2017-12-21 BR BR112019012906A patent/BR112019012906A2/pt unknown
- 2017-12-21 EP EP17832250.9A patent/EP3558981B1/en active Active
- 2017-12-21 MA MA055983A patent/MA55983A/fr unknown
- 2017-12-21 US US16/472,377 patent/US10717726B2/en active Active
- 2017-12-21 HU HUE17832250A patent/HUE056540T2/hu unknown
-
2019
- 2019-06-19 IL IL267484A patent/IL267484B/en unknown
- 2019-06-20 CL CL2019001728A patent/CL2019001728A1/es unknown
- 2019-06-21 PH PH12019550111A patent/PH12019550111A1/en unknown
- 2019-07-09 CO CONC2019/0007321A patent/CO2019007321A2/es unknown
-
2020
- 2020-06-08 US US16/895,221 patent/US11098032B2/en active Active
-
2021
- 2021-05-28 AU AU2021203497A patent/AU2021203497B2/en active Active
- 2021-07-06 US US17/367,849 patent/US20210347765A1/en active Pending
- 2021-08-04 HR HRP20211255TT patent/HRP20211255T1/hr unknown
- 2021-08-19 IL IL285729A patent/IL285729B/en unknown
- 2021-08-25 CY CY20211100760T patent/CY1124461T1/el unknown
-
2022
- 2022-02-10 JP JP2022019891A patent/JP7286825B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201991513A1 (ru) | Производные пирана как ингибиторы cyp11a1 (цитохром p450 монооксигеназы 11a1) | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| MX2020007485A (es) | Compuestos antiproliferativos y metodos de uso de los mismos. | |
| UA118149C2 (uk) | Інгібітор jak | |
| TR201901312T4 (tr) | Mcl-1 proteinini inhibe eden tetrahidronaftalen türevleri. | |
| TR201817995T4 (tr) | Nöroakti̇f steroi̇dler ve kullanim yöntemleri̇ | |
| EA201692487A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201591339A1 (ru) | Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы | |
| EA201691421A1 (ru) | Гетероарилы и их применение | |
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| MX2020001719A (es) | Inhibidores macrocíclicos de mcl-1 y metodos de uso. | |
| SG11201900868XA (en) | Ido1 inhibitor and preparation method and application thereof | |
| MX2017008386A (es) | Administración específica del sitio de un inhibidor de btk. | |
| PH12019501639A1 (en) | Jaki selective inhibitors | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
| PH12019501461A1 (en) | Pharmaceutical composition of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma | |
| IN2014MU00303A (ru) | ||
| CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
| PH12017501880A1 (en) | Methods for treating cancer | |
| JOP20190163A1 (ar) | منشط nrf2 | |
| UY36132A (es) | Métodos para terapia de cáncer | |
| AU2017257755A1 (en) | Benzoylglycine derivatives and methods of making and using same |